Theoretically, IL-1β neutralization could also benefit patients with chronic autoinflammatory diseases such as rheumatoid arthritis [48], as well as type 2 diabetes, which is also considered as a chronic low-grade inflammatory disease [49]. This evidence concerns the gene IL1B and rheumatoid arthritis.